ClinicalTrials.gg
CompletedNCT01718353TAXYNERGYUpdated Nov 20, 2017Results posted

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 2 interventional study of DOCETAXEL (XRP6976) and CABAZITAXEL (XRP6258) in Prostate Cancer Metastatic, sponsored by Sanofi. Completed at 19 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-20.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Enrollment
67th of 185
63 · median 39
Started
2013
with 1 other
Phase 2
104 of 193
4 open now
Registered
141st of 193
by date
Lead sponsor
11 of 193
Sanofi

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 67th largest by enrollment of the 185 interventional ones that give a count, is one of 2 that started in 2013, is one of 104 in phase 2, and was the 141st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Docetaxel and cabazitaxel are cancer chemotherapy agents of the taxane drug class. The purpose of this study is to explore the benefit, for treatment of metastatic castration-resistant prostate cancer (mCRPC), of a regimen in which participants begin treatment with either of these two taxane drugs (docetaxel or cabazitaxel, in combination with prednisone) and are switched to the other taxane drug if prostate-specific antigen (PSA) value does not decrease ≥30% after 4 cycles. As defined in study protocol amendment 3, efficacy results are summarized for all participants combined, irrespective of which agent (docetaxel or cabazitaxel) was administered initially, rather than separately for the two groups based on taxane administered initially. One of the primary outcome measures is percentage of participants with a ≥50% sustained decrease from baseline in PSA at any time during the trial. By providing an opportunity for patients to switch taxane based on early PSA response, there may be a difference in result for this measure versus result in a study where it was not possible to switch. The other primary outcome measures are change from baseline in circulating tumor cells (CTCs) biomarkers percent androgen receptor nuclear localization (%ARNL) and microtubule bundling (MTB).

Read the detailed description
  • Participants were treated until progressive disease, unacceptable toxicity, death, or participant's refusal of further study treatment. All participants were followed until death or the study cut-off date, whichever came first.
  • Study cut-off was 1 month after the last participant last treatment.
  • Participants alive at the cut-off date were not followed for overall survival.
03

Conditions studied

  • Prostate Cancer Metastatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - or cytologically-confirmed prostate adenocarcinoma with documented distant (M1 disease).
  • Progressive disease while receiving hormonal therapy or after surgical castration.
  • Effective castration (serum testosterone levels ≤50 ng/dL) by orchiectomy and/or luteinizing hormone releasing hormone agonists or antagonist with or without anti-androgens.

Exclusion criteria

Exclusion criteria:

  • Prior chemotherapy for prostate cancer, except estramustine and /neoadjuvant treatment completed >3 years ago. Prior treatment with sipuleucel-T immunotherapy was allowed at the condition participant did not receive prior chemotherapy.
  • Less than 28 days elapsed from prior treatment with estramustine, radiotherapy or surgery to the time of random allocation.
  • Prior beta isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow.
  • Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of grade >1(National Cancer Institute [NCI CTCAE] v4.03) at the time of random allocation.
  • Less than 18 years of age.
  • (ECOG) performance status >2.
  • History of , uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or .
  • Prior . Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa and pT1) bladder cancer were allowed, as well as any other cancer for which chemotherapy had been completed ≥3 years ago and from which the participant had been disease-free for ≥3 years.
  • Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to random allocation.
  • Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, (NYHA) class III or IV congestive heart failure, stroke or .
  • Any of the following within 3 months prior to random allocation: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
  • Acquired immunodeficiency syndrome (AIDS)-related illnesses or known disease requiring antiretroviral treatment.
  • Any severe acute or chronic medical condition which could impair the ability of the participant to participate in to the study or interfere with interpretation of study results, or participant unable to comply with the study procedures.
  • Concomitant treatment with biphosphonates or denosumab except if the dose had been stable for 4 weeks prior to enrollment.
  • Absence of signed and dated Institutional Review Board (IRB)-approved participant prior to enrollment into the study.
  • Participants with who did not agree to use an accepted and effective method of during the study treatment period. The definition of "effective method of contraception" was based on the investigator's judgment.
  • History of to docetaxel or polysorbate 80.
  • Inadequate organ and bone marrow function.
  • to the use of treatment.
  • Symptomatic peripheral neuropathy grade >2 (NCI CTCAE v.4.03).
  • Treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a two-week was necessary for participants who were already on these treatments).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Docetaxel + Prednisone (Treatment A)

    Docetaxel 75 mg/m\^2 intravenous (IV) infusion on Day 1 of Cycle 1 and every 3 weeks (q3w) thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with \<30% PSA reduction from baseline at the end of Cycle 4 switched to Cabazitaxel 25mg/m\^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.

    Drug: DOCETAXEL (XRP6976) · Drug: Prednisone

  • Experimental
    Cabazitaxel + Prednisone (Treatment B)

    Cabazitaxel 25 mg/m\^2 IV infusion on Day 1 of Cycle 1 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with \<30% PSA reduction from baseline at the end of Cycle 4 switched to Docetaxel 75mg/m\^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.

    Drug: CABAZITAXEL (XRP6258) · Drug: Prednisone

Interventions

  • Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

    Also known as: Taxotere®

  • Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous

    Also known as: Jevtana®

  • Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With PSA Response

    PSA response was defined as ≥50% decrease in PSA levels in both treatment arms from baseline, during the whole treatment, before treatment switch and after treatment switch. PSA progression was defined as decline of PSA from baseline (an increase of ≥25% \[at least 2ng/ml\] over the nadir value, confirmed by a second PSA value at least 3 weeks apart) and no decline of PSA from baseline (an increase of ≥25% \[at least 2ng/ml\] over the baseline value after 12 weeks of treatment, confirmed by a second PSA value at least 3 weeks apart). Because the purpose of this study is to explore the benefit of a regimen in which participants are switched to a different taxane if PSA does not decrease ≥30% after 4 cycles, irrespective of which agent (docetaxel or cabazitaxel) is administered initially, the data for participants who began treatment with docetaxel and for those who began treatment with cabazitaxel were combined for the efficacy analyses.

    Time frame: Baseline, Pre-dose every 3 weeks, 30 days after last treatment administration (End of treatment [EOT]), every 3 months (for 1 year) then every 6 months until PSA progression or study cut-off, whichever was earlier (Maximum duration: 60 weeks)

  2. Drug-target Engagement in Circulating Tumor Cells (CTCs): Change From Baseline at Cycle 1 Day 8 in Percent Androgen Receptor Nuclear Localization (%ARNL) by Categories of PSA Decrease From Baseline (≥50%, Not ≥50%) After Cycle 4

    Analysis of CTCs is a co-primary endpoint. Growth of prostate cancer cells is dependent on sustained androgen receptor (AR) nuclear signaling. Taxanes (e.g., docetaxel and cabazitaxel) may mediate some of their activity in prostate cancer by impairing AR trafficking along the microtubules from the tumor cell cytoplasm into the nucleus, as a result of taxane-induced microtubule bundling (MTB). Blood samples were collected at baseline and post-treatment to allow isolation of CTCs, which were evaluated for tumor cell biomarker measures %ARNL and MTB score. %ARNL was assessed by quantitative analysis of images of CTCs captured by geometrically enhanced differential immunocapture (GEDI). Reduction from baseline in %ARNL (percentage of total cellular AR that is located in the nucleus) may indicate inhibition of AR signaling. Change from baseline in %ARNL at Cycle 1 Day 8 is summarized by categories of participants with PSA decrease from baseline (≥50%, Not ≥50%) after Cycle 4.

    Time frame: Baseline and Cycle 1 Day 8, Cycle 4

  3. Drug-target Engagement in CTCs: Change From Baseline at Cycle 1 Day 8 in MTB by Categories of PSA Decrease From Baseline (≥30%, Not ≥30%) After Cycle 4

    Analysis of CTCs is a co-primary endpoint. Growth of prostate cancer cells is dependent on sustained AR nuclear signaling. Taxanes (e.g., docetaxel and cabazitaxel) may mediate some of their activity in prostate cancer by impairing AR trafficking along the microtubules from the tumor cell cytoplasm into the nucleus, as a result of taxane-induced MTB. Blood samples were collected at baseline and post-treatment to allow isolation of CTCs, which were evaluated for tumor cell biomarker measures %ARNL and MTB score. MTB in images of CTCs captured by GEDI was qualitatively assessed by three independent operators for increase compared with baseline on a scale of 0 to 3 from no to most MTB increase. Increase from baseline in MTB may indicate inhibition of AR signaling. Change from baseline in MTB at Cycle 1 Day 8 is summarized by categories of participants with PSA decrease from baseline (≥30%, Not ≥30%) after Cycle 4.

    Time frame: Baseline and Cycle 1 Day 8, Cycle 4

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time interval between the date of random allocation of the treatment and the date of first documentation of any of the following: radiographic tumor progression (using Modified Response Evaluation Criteria in Solid Tumors \[RECIST1.1\] before any switch and during the study), clinical progression (including skeletal-related events, increasing pain requiring escalation of narcotic analgesics, urinary obstruction), PSA progression or death from any cause. Analysis was performed by Kaplan Meier method.

    Time frame: From Baseline until DP or death due to any cause or study cut off, whichever was earlier (Maximum duration: 60 weeks)

  2. PSA Progression Free Survival

    PSA progression-free survival before any switch and PSA progression free survival during the study was defined as the time interval between the date of Day 1 of Cycle 1 to the date of either first PSA progression or death due to any cause whichever came first. PSA progression was defined as decline of PSA from baseline (an increase of ≥25% \[at least 2ng/mL\] over the nadir value, confirmed by a second PSA value at least 3 weeks apart) and no decline of PSA from baseline (an increase of ≥25% \[at least 2ng/mL\] over the baseline value after 12 weeks of treatment, confirmed by a second PSA value at least 3 weeks apart).

    Time frame: From Baseline until DP or death due to any cause or study cut off date, whichever was earlier (Maximum duration: 60 weeks)

  3. Percentage of Participants With Objective Response

    Time frame: From baseline until DP or study cut off, whichever was earlier (Maximum duration: 60 weeks)

  4. Radiographic Progression-free Survival (rPFS)

    Time frame: From baseline, every 12 weeks until radiological tumor progression or study cut-off, whichever was earlier (Maximum duration: 60 weeks)

  5. Clinical Progression-free Survival (cPFS)

    cPFS was assessed before switch and during the study including skeletal-related events (SRE), increasing pain requiring escalation of narcotic analgesics, urinary obstruction, etc. SRE included pathological fractures and/or spinal cord compression, need for bone irradiation (including radioisotopes or bone surgery), change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the face of increase in pain) to treat bone pain. Pain was assessed using present pain intensity (PPI) scale (0=no pain, up to 5=excruciating pain) and analgesics used for cancer pain (1 point for non-narcotic medications and 4 points for narcotic medications).

    Time frame: Baseline, Pre-dose every 3 weeks, EOT, every 3 months (for 1 year) until first SRE occurrence or death or study cut-off, whichever was earlier (Maximum duration: 60 weeks)

  6. Overall Survival

    Overall survival before switch and overall survival during the study was defined as the time interval from the date of random allocation to the date of death due to any cause until study cut-off date.

    Time frame: From baseline until death due to any cause or study cut-off, whichever was earlier (Maximum duration: 60 weeks)

  7. Percentage of Participants With ≥30% and ≥50% Reduction in PSA Response

    Participants with ≥30% and ≥50% reduction in PSA response from base line were evaluated in participants who were previously treated with a high potency androgen receptor (AR)-targeted agent (AR signaling inhibitor or cytochrome P450 17 alphahydroxylase/17,20lyase \[CYP 17\] inhibitor).

    Time frame: From baseline until DP or study cut-off, whichever was earlier (Maximum duration: 60 weeks)

07

Results

Posted Nov 20, 2017

Participant flow

The study was conducted at 19 centers in Canada and United States. A total of 81 participants were screened between 20 March 2013 and 29 May 2014, of which, 63 participants were randomized and 61 were treated. A total of 18 participants were screen failure mainly due to exclusion criteria met and inclusion criteria not met.

Participant flow — Overall Study
MilestoneDocetaxel + Prednisone (Treatment A)Cabazitaxel + Prednisone (Treatment B)
Started4122
Treated3922
Treated up to end of cycle 43216
Treated from cycle 52325
Completed2917
Not completed125
Withdrew: Lost to follow-up01
Withdrew: Principal investigator's decision104
Withdrew: Randomized but not treated20

Outcome measures

PrimaryPercentage of Participants With PSA Response

PSA response was defined as ≥50% decrease in PSA levels in both treatment arms from baseline, during the whole treatment, before treatment switch and after treatment switch. PSA progression was defined as decline of PSA from baseline (an increase of ≥25% \[at least 2ng/ml\] over the nadir value, confirmed by a second PSA value at least 3 weeks apart) and no decline of PSA from baseline (an increase of ≥25% \[at least 2ng/ml\] over the baseline value after 12 weeks of treatment, confirmed by a second PSA value at least 3 weeks apart). Because the purpose of this study is to explore the benefit of a regimen in which participants are switched to a different taxane if PSA does not decrease ≥30% after 4 cycles, irrespective of which agent (docetaxel or cabazitaxel) is administered initially, the data for participants who began treatment with docetaxel and for those who began treatment with cabazitaxel were combined for the efficacy analyses.

Time frame:
Baseline, Pre-dose every 3 weeks, 30 days after last treatment administration (End of treatment [EOT]), every 3 months (for 1 year) then every 6 months until PSA progression or study cut-off, whichever was earlier (Maximum duration: 60 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With PSA Response
percentage of participantsOverall Population (Treatment A or Treatment B)
PSA response before switch39.7
PSA response after switch15.9
Overall PSA response55.6
PrimaryDrug-target Engagement in Circulating Tumor Cells (CTCs): Change From Baseline at Cycle 1 Day 8 in Percent Androgen Receptor Nuclear Localization (%ARNL) by Categories of PSA Decrease From Baseline (≥50%, Not ≥50%) After Cycle 4

Analysis of CTCs is a co-primary endpoint. Growth of prostate cancer cells is dependent on sustained androgen receptor (AR) nuclear signaling. Taxanes (e.g., docetaxel and cabazitaxel) may mediate some of their activity in prostate cancer by impairing AR trafficking along the microtubules from the tumor cell cytoplasm into the nucleus, as a result of taxane-induced microtubule bundling (MTB). Blood samples were collected at baseline and post-treatment to allow isolation of CTCs, which were evaluated for tumor cell biomarker measures %ARNL and MTB score. %ARNL was assessed by quantitative analysis of images of CTCs captured by geometrically enhanced differential immunocapture (GEDI). Reduction from baseline in %ARNL (percentage of total cellular AR that is located in the nucleus) may indicate inhibition of AR signaling. Change from baseline in %ARNL at Cycle 1 Day 8 is summarized by categories of participants with PSA decrease from baseline (≥50%, Not ≥50%) after Cycle 4.

Time frame:
Baseline and Cycle 1 Day 8, Cycle 4
Reported as:
Mean · percentage ARNL
Drug-target Engagement in Circulating Tumor Cells (CTCs): Change From Baseline at Cycle 1 Day 8 in Percent Androgen Receptor Nuclear Localization (%ARNL) by Categories of PSA Decrease From Baseline (≥50%, Not ≥50%) After Cycle 4
percentage ARNLOverall Population (Treatment A or Treatment B)
PSA decreased ≥50% at Cycle 4-17.58 ± 21.54
PSA not decreased ≥50% at Cycle 42.30 ± 11.16
Statistical analysis
  • Overall Population (Treatment A or Treatment B) · ANOVA · p = 0.02
SecondaryProgression Free Survival (PFS)

PFS was defined as the time interval between the date of random allocation of the treatment and the date of first documentation of any of the following: radiographic tumor progression (using Modified Response Evaluation Criteria in Solid Tumors \[RECIST1.1\] before any switch and during the study), clinical progression (including skeletal-related events, increasing pain requiring escalation of narcotic analgesics, urinary obstruction), PSA progression or death from any cause. Analysis was performed by Kaplan Meier method.

Time frame:
From Baseline until DP or death due to any cause or study cut off, whichever was earlier (Maximum duration: 60 weeks)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsOverall Population (Treatment A or Treatment B)
Before switch4.1 (3.81 to NA)
Whole treatment continuum9.1 (4.93 to 11.70)
SecondaryPSA Progression Free Survival

PSA progression-free survival before any switch and PSA progression free survival during the study was defined as the time interval between the date of Day 1 of Cycle 1 to the date of either first PSA progression or death due to any cause whichever came first. PSA progression was defined as decline of PSA from baseline (an increase of ≥25% \[at least 2ng/mL\] over the nadir value, confirmed by a second PSA value at least 3 weeks apart) and no decline of PSA from baseline (an increase of ≥25% \[at least 2ng/mL\] over the baseline value after 12 weeks of treatment, confirmed by a second PSA value at least 3 weeks apart).

Time frame:
From Baseline until DP or death due to any cause or study cut off date, whichever was earlier (Maximum duration: 60 weeks)
Reported as:
Median · months
PSA Progression Free Survival
monthsOverall Population (Treatment A or Treatment B)
Before switchNA (3.09 to NA)
whole treatment continuum12.4 (8.31 to NA)
SecondaryPercentage of Participants With Objective Response
Time frame:
From baseline until DP or study cut off, whichever was earlier (Maximum duration: 60 weeks)

No measurements were reported for this outcome.

SecondaryRadiographic Progression-free Survival (rPFS)
Time frame:
From baseline, every 12 weeks until radiological tumor progression or study cut-off, whichever was earlier (Maximum duration: 60 weeks)
Reported as:
Median · months
Radiographic Progression-free Survival (rPFS)
monthsOverall Population (Treatment A or Treatment B)
Radiographic Progression-free Survival (rPFS)NA (NA to NA)
SecondaryClinical Progression-free Survival (cPFS)

cPFS was assessed before switch and during the study including skeletal-related events (SRE), increasing pain requiring escalation of narcotic analgesics, urinary obstruction, etc. SRE included pathological fractures and/or spinal cord compression, need for bone irradiation (including radioisotopes or bone surgery), change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the face of increase in pain) to treat bone pain. Pain was assessed using present pain intensity (PPI) scale (0=no pain, up to 5=excruciating pain) and analgesics used for cancer pain (1 point for non-narcotic medications and 4 points for narcotic medications).

Time frame:
Baseline, Pre-dose every 3 weeks, EOT, every 3 months (for 1 year) until first SRE occurrence or death or study cut-off, whichever was earlier (Maximum duration: 60 weeks)
Reported as:
Median · months
Clinical Progression-free Survival (cPFS)
monthsOverall Population (Treatment A or Treatment B)
Before switchNA (7.16 to NA)
Whole treatment continuumNA (NA to NA)
SecondaryOverall Survival

Overall survival before switch and overall survival during the study was defined as the time interval from the date of random allocation to the date of death due to any cause until study cut-off date.

Time frame:
From baseline until death due to any cause or study cut-off, whichever was earlier (Maximum duration: 60 weeks)
Reported as:
Median · Months
Overall Survival
MonthsOverall Population (Treatment A or Treatment B)
Before switch8.8 (4.01 to NA)
whole treatment continuumNA (14.03 to NA)
SecondaryPercentage of Participants With ≥30% and ≥50% Reduction in PSA Response

Participants with ≥30% and ≥50% reduction in PSA response from base line were evaluated in participants who were previously treated with a high potency androgen receptor (AR)-targeted agent (AR signaling inhibitor or cytochrome P450 17 alphahydroxylase/17,20lyase \[CYP 17\] inhibitor).

Time frame:
From baseline until DP or study cut-off, whichever was earlier (Maximum duration: 60 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With ≥30% and ≥50% Reduction in PSA Response
percentage of participantsOverall Population (AR-target Agent Treated)Overall Population (Non AR-target Agent Treated)
≥30% reduction52.074.3
≥50% reduction44.068.6
PrimaryDrug-target Engagement in CTCs: Change From Baseline at Cycle 1 Day 8 in MTB by Categories of PSA Decrease From Baseline (≥30%, Not ≥30%) After Cycle 4

Analysis of CTCs is a co-primary endpoint. Growth of prostate cancer cells is dependent on sustained AR nuclear signaling. Taxanes (e.g., docetaxel and cabazitaxel) may mediate some of their activity in prostate cancer by impairing AR trafficking along the microtubules from the tumor cell cytoplasm into the nucleus, as a result of taxane-induced MTB. Blood samples were collected at baseline and post-treatment to allow isolation of CTCs, which were evaluated for tumor cell biomarker measures %ARNL and MTB score. MTB in images of CTCs captured by GEDI was qualitatively assessed by three independent operators for increase compared with baseline on a scale of 0 to 3 from no to most MTB increase. Increase from baseline in MTB may indicate inhibition of AR signaling. Change from baseline in MTB at Cycle 1 Day 8 is summarized by categories of participants with PSA decrease from baseline (≥30%, Not ≥30%) after Cycle 4.

Time frame:
Baseline and Cycle 1 Day 8, Cycle 4
Reported as:
Mean · units on a scale
Drug-target Engagement in CTCs: Change From Baseline at Cycle 1 Day 8 in MTB by Categories of PSA Decrease From Baseline (≥30%, Not ≥30%) After Cycle 4
units on a scaleOverall Population (Treatment A or Treatment B)
PSA decreased ≥30% at Cycle 40.69 ± 0.87
PSA not decreased ≥30% at Cycle 40.09 ± 0.18
Statistical analysis
  • Overall Population (Treatment A or Treatment B) · ANOVA · p = 0.0927

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel + Prednisone (Treatment A) - Throughout—10/27 (37%)26/27 (96.3%)
Cabazitaxel + Prednisone (Treatment B) - Throughout—8/19 (42.1%)18/19 (94.7%)
Switched Population (Treatment A to B or Treatment B to A)—9/15 (60%)15/15 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventDocetaxel + Prednisone (Treatment A) - ThroughoutCabazitaxel + Prednisone (Treatment B) - ThroughoutSwitched Population (Treatment A to B or Treatment B to A)
Febrile neutropeniaBlood and lymphatic system disorders3/272/190/15
Urinary tract infectionInfections and infestations0/272/191/15
SepsisInfections and infestations0/272/190/15
Hip fractureInjury, poisoning and procedural complications2/270/190/15
UrosepsisInfections and infestations0/270/191/15
Anaphylactoid reactionImmune system disorders0/270/191/15
Nerve compressionNervous system disorders0/270/191/15
Supraventricular tachycardiaCardiac disorders0/270/191/15
Deep vein thrombosisVascular disorders0/270/191/15
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/271/191/15
Most frequent other events
Showing 10 of 145
Most frequent other events
EventDocetaxel + Prednisone (Treatment A) - ThroughoutCabazitaxel + Prednisone (Treatment B) - ThroughoutSwitched Population (Treatment A to B or Treatment B to A)
FatigueGeneral disorders18/2713/1910/15
DiarrhoeaGastrointestinal disorders13/2712/199/15
NauseaGastrointestinal disorders8/2710/197/15
VomitingGastrointestinal disorders3/277/194/15
Neuropathy peripheralNervous system disorders9/276/193/15
ConstipationGastrointestinal disorders3/276/195/15
AlopeciaSkin and subcutaneous tissue disorders9/275/195/15
HaematuriaRenal and urinary disorders1/272/195/15
Back painMusculoskeletal and connective tissue disorders5/276/194/15
Decreased appetiteMetabolism and nutrition disorders8/274/194/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Docetaxel + Prednisone (Treatment A)Cabazitaxel + Prednisone (Treatment B)Total
Mean69.9 ± 7.869.2 ± 9.569.7 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel + Prednisone (Treatment A)Cabazitaxel + Prednisone (Treatment B)Total
Female000
Male412263
08

Study locations

19 sites
  • Investigational Site Number 840003
    Birmingham, Alabama 35294-3300, United States
  • Investigational Site Number 840102
    Washington, D.C., District of Columbia 20016-2695, United States
  • Investigational Site Number 840005
    Indianapolis, Indiana 46202, United States
  • Investigational Site Number 840025
    Metairie, Louisiana 70006, United States
  • Investigational Site Number 840002
    Baltimore, Maryland 21230, United States
  • Investigational Site Number 840007
    Bethesda, Maryland 20817, United States
  • Investigational Site Number 840017
    Rockville, Maryland 20850, United States
  • Investigational Site Number 840010
    Cherry Hill, New Jersey 08003, United States
  • Investigational Site Number 840015
    East Orange, New Jersey 07018, United States
  • Investigational Site Number 840001
    New York, New York 10021, United States
  • Investigational Site Number 840013
    New York, New York 10029-6574, United States
  • Investigational Site Number 840009
    Charleston, South Carolina 29414, United States
  • Investigational Site Number 840012
    Seattle, Washington 98109, United States
  • Investigational Site Number 840004
    Madison, Wisconsin 53705, United States
  • Investigational Site Number 124001
    Edmonton, Alberta T6G 1Z2, Canada
  • Investigational Site Number 124004
    Montreal, Quebec H2L 4M1, Canada
  • Investigational Site Number 124002
    Montreal, Quebec H2W1S6, Canada
  • Investigational Site Number 124006
    Québec, Quebec G1R 2J6, Canada
  • Investigational Site Number 124005
    Sherbrooke, Quebec J1H 5N4, Canada
09

References and documents

Publications

  • Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P. Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clin Cancer Res. 2019 Mar 15;25(6):1880-1888. doi: 10.1158/1078-0432.CCR-18-0320. Epub 2018 Oct 9. PubMed 30301829 ↗
  • Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; TAXYNERGY Investigators. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer. J Clin Oncol. 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. Epub 2017 Jun 20. PubMed 28632486 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2017, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2012
First posted
Oct 31, 2012
Start
Mar 2013
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Nov 20, 2017
Last update
Nov 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01718353
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 31, 2012
Start date
Mar 2013
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Nov 20, 2017
Last update
Nov 20, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cabazitaxel

Start the discussion